Status | Discontinued |
Process | STA pre-2018 |
Referral date | 01 June 2008 |
Topic area |
|
Provisional Schedule
Closing date for invited submissions / evidence submission: | TBC |
1st appraisal committee meeting: | TBC |
Project Team
Communications manager: | TBC |
Executive Lead: | TBC |
Project manager: | TBC |
Technical Lead: | TBC |
Consultees
Manufacturers/sponsors | Bristol Myers Squibb Pharmaceuticals (abatacept) |
Others | Cardiff LHB |
Department of Health | |
Doncaster PCT | |
Welsh Assembly Government | |
Patient/carer groups | Action for Children |
Action for Sick Children | |
Action on Pain | |
Afiya Trust | |
Arthritic Association | |
Arthritis and Musculoskeletal Alliance (ARMA) | |
Arthritis Care | |
BackCare | |
Black Health Agency | |
British Ethnic Health Awareness Foundation (BEHAF) | |
Children’s Society | |
Children’s Chronic Arthritis Association | |
Chinese National Healthy Living Centre | |
Confederation of Indian Organisations | |
Equalities National Council | |
Leonard Cheshire Disability | |
Muslim Council of Great Britain | |
Muslim Health Network | |
National Children’s Bureau | |
National Parent and Carer Council | |
National Parent Partnership Network | |
National Rheumatoid Arthritis Society | |
Pain Concern | |
Pain Relief Foundation | |
RADAR - Royal Association for Disability and Rehabilitation | |
Skill: National Bureau for Students with Disabilities | |
South Asian Health Foundation | |
Specialised Healthcare Alliance | |
WellChild | |
Professional groups | British Health Professionals in Rheumatology |
British Institute of Musculoskeletal Medicine | |
British Orthopaedic Association | |
British Pain Society | |
British Society for Paediatric and Adolescent Rheumatology | |
British Society for Rheumatology | |
British Society of Rehabilitation Medicine | |
College of Occupational Therapists | |
Physiotherapy Pain Association | |
Primary Care Rheumatology Society | |
Rheumatoid Arthritis Surgical Society | |
Royal Society of Anaesthetists | |
Royal College of General Practitioners | |
Royal College of Nursing | |
Royal College of Paediatrics & Child Health | |
Royal College of Pathologists | |
Royal College of Physicians | |
Royal College of Surgeons | |
Royal Pharmaceutical Society | |
Royal Society of Medicine – Intellectual Disabilities Forum | |
United Kingdom Clinical Pharmacy Association |
Commentators
Associated Guideline Groups | National Clinical Guidelines Centre for Acute and Chronic Conditions |
Associated Public Health Groups | None |
Comparator manufacturer(s) | Abbott Pharmaceuticals (adalimumab) |
Generics (UK) (sulfasalazine) | |
IVAX Pharmaceuticals (sulfasalazine) | |
Mayne Pharma (methotrexate) | |
Medac UK (methotrexate) | |
Novartis Pharmaceuticals (ciclosporin) | |
Pfizer (sulfasalazine, methotrexate) | |
Sanofi Aventis (hydroxychloroquine, leflunomide) | |
Schering-Plough (infliximab) | |
Teva UK (sulfasalazine) | |
Wockhardt UK (methotrexate) | |
Wyeth Laboratories (etanercept) | |
Evidence Review Group | NHS Centre for Reviews & Dissemination and Centre for Health Economics –York |
National Institute for Health Research Health Technology Assessment Programme | |
General | Board of Community Health Councils in Wales |
British National Formulary | |
Department of Health,Social Services and Public Safety for Northern Ireland | |
Medicines and Healthcare products Regulatory Agency (MHRA) | |
National Association of Primary Care | |
National Public Health Service for Wales | |
NHS Alliance | |
NHS Confederation | |
NHS Purchasing and Supply Agency | |
NHS Quality Improvement Scotland | |
Scottish Medicines Consortium | |
Relevant research groups | Arthritis Research Campaign |
Bone Research Society | |
MRC Clinical Trials Unit | |
National Institute of Health Research | |
United Kingdom Clinical Research Network |
Timeline
Key events during the development of the guidance:
Date | Update |
---|---|
7 August 2009 | The above topic was referred to NICE as part of the 17th wave referrals. The manufacturer of abatacept has informed us that they are not in a position to submit evidence in line with the current schedule for this STA because of a delay in the regulatory process. This STA is therefore suspended. |
7 July 2010 | The marketing authorisation for abatacept in this therapeutic area suggests limited use of this drug for a small population of those with juvenile idiopathic arthritis. Following discussions with the Department of Health, we have therefore concluded that this topic should be removed from the work programme. |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance